L. Zeverijn

发表

Maternal recall of a history of early-onset preeclampsia, late-onset preeclampsia, or gestational hypertension: a validation study

P. Teunissen, C. D. de Groot, A. Bokslag, 2020, Hypertension in pregnancy.

8. Maternal recall of a history of early-onset preeclampsia, late-onset preeclampsia or gestational hypertension: a questionnaire study

P. Teunissen, C. D. de Groot, A. Bokslag, 2018, Pregnancy Hypertension.

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.

E. Smit, P. Roepman, H. Gelderblom, 2022, European journal of cancer.

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

E. Voest, H. Gelderblom, A. Huitema, 2022, Cancer Chemotherapy and Pharmacology.

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

E. Voest, H. Gelderblom, A. Huitema, 2022, Cancer Chemotherapy and Pharmacology.

Patients With Rare Cancers in the Drug Rediscovery Protocol (DRUP) benefit from Genomics - Guided Treatment Genomics – Guided Treatment of Rare Cancer Patients in DRUP

Henk, E. Cuppen, E. Smit, 2022 .

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

Marieke E. Ijsselsteijn, L. Wessels, J. G. van den Berg, 2023, Nature.

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

P. Roepman, E. Voest, H. Gelderblom, 2021, Clinical Cancer Research.

Can Drug Repurposing Accelerate Precision Oncology?

M. Garnett, E. Voest, L. Schipper, 2022, Cancer discovery.

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

P. Roepman, H. Gelderblom, H. Verheul, 2023, BMC Cancer.

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

E. Cuppen, E. Smit, P. Roepman, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D‐CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials

R. Simes, P. Roepman, H. Gelderblom, 2023, International journal of cancer.

Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions

M. Kok, L. Zeverijn, F. Opdam, 2023, The Oncologist.

Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy

P. Roepman, L. Hoes, P. Snaebjornsson, 2024, The Journal of pathology.

Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).

P. Roepman, L. Zeverijn, V. Noort, 2024, European journal of cancer.

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

H. Bloemendal, M. Labots, M. Jalving, 2024, The Lancet regional health. Europe.